How Much Do Weight Loss Injections Cost? $25 Copay to $349 Self-Pay, Dose by Dose

Every headline about weight loss injections tells you they cost $1,300 a month. Every savings ad tells you they cost $25. Both are technically true. Neither tells you what you’ll pay, the only number that matters when you’re staring at a family budget that also has to cover soccer cleats and the water heater.

So here’s the real breakdown: what you’ll pay by dose, and what your insurance status and pharmacy choice do to it. Every promotional price comes with its expiration date attached, because a deal without a deadline isn’t a price, it’s marketing. And the $199 number everyone headlines? That’s a two-fill starter rate. It goes up.

A quick note on why this matters right now: as of late 2025, 12% of US adults reported using a GLP-1, a share that has doubled over the previous 18 months, per the KFF Health Tracking Poll from November 14, 2025. These prices are landing in actual household budgets, not just in press releases. Everything below is US pricing only.

One more thing from my side of the keyboard. Around here we budget in years, not months. A $349 monthly number hides what it really costs for a year. That annual figure decides whether this is doable. I’ll do that math for you at the end.

What weight loss injections cost per month right now

Here’s the direct answer, and it’s a ladder, not a single number. Without insurance, list prices run roughly $900 to $1,300+ per month, and there’s no generic semaglutide available to undercut them. But the manufacturer cash-pay programs have cut that dramatically, and the honest answer depends entirely on which dose you end up on.

Wegovy self-pay, through NovoCare Pharmacy:

• The pill, $149/month for the 1.5 mg and 4 mg doses. One catch: the 4 mg price is only $149 until August 31, 2026. After that it’s $199/month. For the pill, one month means one bottle of 30 tablets.
• The pens, $199/month introductory rate for first-time patients on the 0.25 mg and 0.5 mg starter doses. That intro covers your first 2 monthly fills through December 31, 2026. Then it’s $349/month standard for doses from 0.25 mg up through 2.4 mg, and $399/month for Wegovy HD 7.2 mg. For the pens, one month means one box of 4 pens.

Some context on where these came from: Novo Nordisk announced the whole restructure on November 17, 2025. The $199 intro ran November 17, 2025 through March 31, 2026. The standard cash price dropped from $499 to $349. Ozempic’s 2 mg dose stayed at $499. Existing self-pay patients got the price cut too, which was a nice change from these programs usually only helping new customers.

How does that stack against the other brands paying cash? Zepbound’s direct-to-consumer price is $299 for the starting dose and $449 for higher doses, per Eli Lilly (reported by NPR on November 6, 2025). Foundayo, an oral GLP-1 the FDA approved on April 1, 2026, lists at up to about $350/month. So the cheapest legitimate cash options right now are the Wegovy pill at $149 and Zepbound’s starting dose at $299.

And remember: no generic Ozempic or Wegovy exists, and these are long-term meds. Every monthly figure multiplies.

One pattern I’ve noticed in the cash-pay crowd that’s worth passing along: a lot of people anchor on the $199 intro price and then get surprised at pickup when their dose tier doesn’t match the promotion. The intro only applies to the two lowest pen doses. If you’re heading toward 1.7 mg or 2.4 mg, your number was always going to be $349.

Why the same drug has different prices

Here’s the part that explains half the denial letters out there. Ozempic and Wegovy both contain semaglutide, which is a GLP-1, meaning a drug that mimics a natural hormone involved in blood-sugar balance. Wegovy is just the same molecule at higher doses. Same ingredient, different paperwork.

The paperwork is everything. Ozempic carries FDA approval for type 2 diabetes, plus reducing cardiovascular risk and protecting kidneys. Using it for weight loss is what’s called “off-label,” which means the FDA hasn’t approved it for that purpose, and insurers generally won’t pay for off-label prescriptions. Wegovy is the brand that carries the weight-loss approval, so it’s the one insurance will consider for obesity.

And Wegovy’s approvals go beyond the scale: chronic weight management in adults and kids 12 and up with obesity (the pill is adults only), cardiovascular risk reduction in adults with heart disease plus obesity or overweight, and MASH, a serious liver disease, under an accelerated approval, injection only.

Two practical takeaways. First, don’t combine semaglutide products, ever. That’s a safety rule, but it’s also a cost point: paying for two versions of the same drug is literally paying for duplication. Second, and this is the big one: the diagnosis code, not the drug, determines coverage.

The right question for your insurer isn’t “is Wegovy covered.” It’s “what’s covered for my diagnosis.” A pattern worth knowing: people assume one brand’s coverage decision predicts another’s, but denials hinge on the indication. A plan may cover Wegovy but not Ozempic or Mounjaro, or the reverse. Your cousin’s denial tells you nothing about your plan.

Paying with insurance: the $25 copay card and what 2026 coverage looks like

The good news first, because it’s genuinely good: with commercial insurance and the manufacturer’s copay card, you can pay as little as $25 per month, with savings capped at $100 per month. This is the coupon-in-the-junk-drawer moment. But that $25 floor is conditional three ways, and I’d rather you know now than at the pharmacy counter.

One: your plan’s base copay determines how much the card actually saves you. If your plan already charges you less than the card’s cap, the card isn’t doing much. Two: you need commercial insurance, meaning an employer plan or a Marketplace plan. Medicare, Medicaid, VA, Tricare, similar government programs, and full cash payers are all excluded.

Yeah, this part just is what it is. Three: the offer only applies to FDA-approved uses, which matters if you’re reading this for the weight-loss angle.

Ozempic’s version of the card works slightly differently: the copay can drop to $25, but only for a 1-, 2-, or 3-month supply filled at once, and only for type 2 diabetes. That diabetes condition is the catch people miss. The offer runs for up to 48 months, so it’s a long runway, not a teaser.

• Enrollment: the digital savings offer online, or enroll by text message: send SAVE to 83757. Message and data rates may apply; send HELP for help, STOP to quit.
• The honest range on commercial insurance: Ozempic typically runs $0 to $1,029 per month depending on your deductibles, coinsurance, and copays. Insurance is a wide range, not a number. And here’s the counterintuitive bit: sometimes paying cash is cheaper than going through your insurance. Nobody expects that, but it happens.
• Track the changing offers: signing up for WEGOVY INSIDER gets you updates on savings offers as they shift. Low-key useful, no pressure.

Now the coverage reality, because it’s not pretty. A 2024 KFF analysis found just 1% of Marketplace plans included Wegovy or Saxenda for weight loss, and none covered Zepbound. In 2026, only 26 of 300 carriers cover obesity GLP-1s, mostly restricted to BMI of 40 or higher. For scale, that’s roughly 240 lbs at 5’5″ or 300 lbs at 6 feet.

Employer coverage is flatlining too. A 2026 survey of 307 US employers (reported by Reuters on June 11, 2026) found 60% cover GLP-1s for diabetes. 36% cover them for weight loss, flat from 2025, and somewhere between 5% and 10% intend to drop weight-loss coverage by 2027. That’s retrenchment, not expansion.

The silver lining: even when the drugs get denied, insurance may still cover behavioral change, nutrition, and exercise programs. Worth asking about before you assume the answer is a flat no.

And between the copay card and the cash price sits a two-step gate: prior authorization (a permission slip your doctor submits to the insurer explaining why you need this drug) and, if that fails, the appeal process. More on both in the playbook below.

Medicare: the $50 Bridge program and its strings

For parents and grandparents on Medicare, here’s the genuinely good news: eligible Medicare patients pay $50 per month for the Wegovy pen or pill under the Medicare GLP-1 Bridge. It’s a temporary federal program: July 1, 2026 through December 31, 2027, nationwide in all states and territories. The $50 covers every dose strength of both the pen and the pill. The $50 applies per 28- or 30-day supply, which is basically a month, but now nobody’s surprised at refill four. Full details live at wegovybridge.novomedlink.com.

Now the strings, in plain English:

• Clinical criteria, set by CMS (the agency that runs Medicare): BMI of 35 or higher; or 30 or higher with certain conditions like heart failure, uncontrolled hypertension, or chronic kidney disease; or 27 or higher with prediabetes or a prior heart attack, stroke, or peripheral artery disease. Age 18 and up.
• Plan enrollment: you need to be in a standalone drug plan (a PDP) or a Medicare Advantage plan with drug coverage in 2026.
• Paperwork: your doctor has to submit a prior authorization, and the prescription has to be for a covered FDA-approved use. Off-label won’t qualify. And meeting the criteria isn’t a coverage guarantee; the government sets the bar, and passing it doesn’t auto-approve you.
• Ozempic is not in the Bridge. It covers only certain FDA-approved weight-loss GLP-1s: Foundayo (oral), the Wegovy pen and pill, and the Zepbound KwikPen. Ozempic may still be covered under Part D for its approved uses, so there are two doors, they just have different prices.
• The fine print that bites at tax season: the $50 does NOT count toward your Part D deductible or the 2026 $2,100 out-of-pocket maximum. Seniors are discovering this the hard way, and now you won’t be one of them.

For anyone on a Part D plan, the practical move is simple: ask your doctor about Wegovy, which has the same active ingredient as Ozempic, on the Bridge. That one fact does all the work. Just remember this program has an end date: December 31, 2027.

Medicaid and state coverage: a pullback, not a patchwork

The baseline first: most state Medicaid programs cover GLP-1s like Ozempic for type 2 diabetes, so the diabetes door is usually open. Weight-loss coverage, though, is decided state by state and often restricted or requires extra steps first. Your cousin in another state genuinely had a different experience. The honest move is one phone call to your state plan.

Now the pullback, and it’s real. Sixteen states covered weight-loss GLP-1s as of 2025. In 2026, California, New Hampshire, Pennsylvania, and South Carolina ended coverage, Michigan imposed a BMI 40-or-higher requirement, and Rhode Island eliminates coverage starting October 2026, a move the American Diabetes Association criticized. Four states dropping it in a single year is not a rounding error.

Some context on why the Marketplace side looks similar: most states’ benchmark plans haven’t been updated since 2017, and North Dakota is the only state whose benchmark includes GLP-1 weight-loss coverage, effective 2025. State legislatures are poking at this: 2026 measures include enacted items like Colorado’s large-group buy-up option plus activity in Louisiana, Maryland, Utah, an Alabama study, and Arizona, with pending bills in California (SB 535), Illinois, New Jersey, and Pennsylvania. That tracking is from healthinsurance.org and the landscape is moving, so treat it as a snapshot, not scripture.

Here’s the budgeting point I keep coming back to: coverage can vanish mid-treatment. That’s a risk no monthly price quote captures, and it’s exactly the kind of thing to plan a fallback around before you rely on Medicaid weight-loss coverage.

How to pay less: the savings playbook, step by step

The difference between paying $1,300 a month and paying $25 is rarely luck. It’s a sequence most people never run because nobody tells them the order of operations. So here it is.

1. Check your formulary before the appointment. A formulary is just the list of drugs your plan covers. Call your insurer and ask two questions: which weight-loss medicines are on the formulary for chronic weight loss, and what’s my monthly copay. Many plans cover no weight-loss drugs at all, though some are starting to. Doing this homework first means the doctor’s appointment actually counts.
2. Verify your actual number. Wegovy’s coverage lookup tool shows whether your plan covers it and your estimated cost, in a few minutes. Or call the insurer directly; there’s a downloadable guide with the right questions to ask. Or get a free NovoCare cost estimate: 1-844-Novo4Me (1-844-668-6463), Monday through Friday 8 am to 11 pm, Saturday 11 am to 7 pm EST, or the 24/7 online form, which usually answers in minutes. Have your insurance info, your provider’s name, and ID details handy. Night-owl parents: the online form works at 11 pm, no phone voice required.
3. Make the appointment. Every weight-loss medicine requires a prescription except alli (orlistat), the over-the-counter exception. If it looks like Ozempic won’t be covered for weight loss, ask about FDA-approved alternatives: Wegovy, Zepbound, or Saxenda. And to be plain: weight-loss meds aren’t right for everyone, for medical and other reasons. This is a conversation with your provider, not a commitment.
4. If denied: prior authorization, then appeal, then HR. The prior auth form explains the medical reason you need this drug over others, and it genuinely improves the coverage odds. If that gets rejected, there’s usually an appeal. If the plan still won’t budge, your doctor can request coverage from your HR department. Your employer picks the plan, so your employer can hear about it, and there’s a downloadable sample letter so you’re not staring at a blank page at midnight.
5. At the pharmacy counter. Before you pay, ask your pharmacist to compare all pricing options. Something like: could you run through every pricing option before I pay for this Wegovy pill? Two minutes, real money. Also consider enrolling in the digital savings offer by text message: send SAVE to 83757 (it includes optional refill reminders; HELP and STOP manage it).
6. Where cash-pay happens. The self-pay offers are right on ozempic.com and wegovy.com, no hunting. NovoCare Pharmacy does home delivery or CVS pickup at 1-888-809-3942. If the name CoAssist Pharmacy shows up on your paperwork, that’s just the dispensing pharmacy behind NovoCare, not a separate option to evaluate. Partners working directly with Novo Nordisk include Costco, GoodRx, WeightWatchers, Ro, LifeMD, and eMed. And if you’re uninsured and stressed about money: financial assistance based on income may provide free or lower-cost medication. That “may” is doing real work, but it’s worth the ask.

One broader note: many drug makers are now offering lower cash prices for GLP-1s. The market may finally be blinking on price, which could make these meds reachable for people paying out of pocket. Could. Verify before you budget around it.

Comparing your options: price versus results

Start with the approved list, because that’s what insurance actually reads. For weight loss: Saxenda (liraglutide), Wegovy (semaglutide) as an injection and a pill, Zepbound (tirzepatide, the weight-loss-approved brand of Mounjaro’s molecule), and Foundayo (oral, approved April 1, 2026). Mounjaro holds no weight-loss approval from the FDA despite studies showing results, so it runs into the same off-label coverage wall as Ozempic.

Now the numbers, with the caveat that these come from separate trials, not head-to-head studies: Zepbound trials showed average weight loss of up to 22.5%; Wegovy HD reached 20.7%, the oral Wegovy pill 16.6%, and the oral Foundayo pill 11.1%. “Average” and “up to” are doing heavy lifting in that sentence, but the spread is real.

Quickly, the diabetes-indicated GLP-1s, since your doctor might name them: Ozempic plus Adlyxin, Bydureon BCise, Byetta, Trulicity, and Victoza, and Rybelsus, a once-daily semaglutide tablet first approved in September 2019 for type 2 diabetes that can also lead to weight loss. All of these are once-weekly injections under the skin (stomach, thigh, or upper arm) or once-daily tablets, and your provider teaches you the injection at home, so nobody’s figuring out the needle alone. On Ozempic, the pens hold 4 weekly doses and last a month, which is why “a month” looks the way it does.

Here’s the value framing that matters for a family budget: a cheaper monthly price isn’t automatically the better choice. Zepbound’s 22.5% average versus oral Foundayo’s 11.1% is a real difference when treatment is long-term and no semaglutide generic exists. Compare price per outcome, not just price per month. If you want the deeper dive on how these actually work in the body, we’ve got a separate explainer on how weight loss injections work.

Why prices are falling: the White House deals and TrumpRx

On November 6, 2025, Novo Nordisk and Eli Lilly struck pricing deals with the White House. The terms: $245 per month pricing pledged to Medicare and Medicaid, with $50 Medicare copays starting in April; states can opt in for Medicaid; starting doses of future obesity pills at $149 per month via Medicare, Medicaid, and TrumpRx; discounted drugs for the uninsured through TrumpRx, averaging about $350 per month for injectables and trending to $245 within 24 months; and a three-year tariff exemption for both companies. Eli Lilly separately cut Zepbound’s direct-to-consumer price to $299 for the starting dose and $449 for higher doses.

The reaction, exactly as NPR reported it: Dr. Oz claimed the deals would be budget-neutral within two years. AMA president Dr. Bobby Mukkamala praised the expanded access. USC economist Geoffrey Joyce noted that manufacturers agreed partly for political reasons and market expansion.

My honest read: this cash-price collapse isn’t a market victory, it’s a negotiated deal phasing in on a schedule. That’s exactly why the price cuts arrive in dated phases, and it’s why readers who understand the timeline can time their purchase channel instead of assuming today’s price is tomorrow’s. The TrumpRx trajectory especially is a reason for patience if your budget can wait.

Budgeting for weight loss injections in a real family budget

This is the part I actually care about, because the monthly figure tells only half the story. Households don’t budget in months. We budget in can we absorb this and still do everything else this year. So let me annualize the real figures.

Self-pay at the standard $349 rate is about $4,188 a year. The lowest pill tier at $149 is about $1,788 a year. The insured $25 copay is $300 a year. Same drug, same year, three completely different line items. Four thousand dollars is a vacation, or a dental procedure we’ve been putting off, or a decent chunk of a car repair fund. That’s the honest frame for what $349/month actually is.

Now the trap, and it’s the single most common budgeting error I see in this space: planning around the introductory price. The $199 starter rate steps up to $349 after two fills. If you build your year around $199 and don’t see the step-up coming, you’ve more than doubled your year-two budget by accident. Plan around the standard rate and treat anything cheaper as a bonus.

And because there’s no generic semaglutide and treatment is typically long-term, monthly costs compound into four- and five-figure annual totals. There’s no hack for this part. The fallback logic, given the coverage pullback documented above: budget around the self-pay price you could actually sustain, not the coverage you hope to get. There are dated reasons for optimism, the TrumpRx trajectory and the Bridge pilot among them, but today’s budget should use today’s verified price.

Safety and fine print that travels with the price

Every dollar figure in this article comes with strings attached, and this section collects them in one place. Some are medical, like the warnings your doctor screens for before writing the prescription. Some are contractual, like the fine print that lets Novo Nordisk modify or cancel a savings program at any time. Either kind can turn a cheap month into a wasted purchase.

What to check before you spend a dollar

Safety stuff is cost stuff in disguise. If a contraindication surfaces after you’ve bought a month, you’ve potentially wasted a $349 to $1,300 purchase. Screening with your doctor first is a budgeting step, full stop.

The headline warning: rodent studies showed possible thyroid tumors including medullary thyroid cancer; whether these medicines cause that cancer in humans is unknown. Don’t use them if you or a family member has had MTC or MEN 2 syndrome, or if you’ve had a serious allergic reaction to semaglutide. Beyond that, the serious-stuff list includes pancreatitis, low blood sugar (riskier if you’re also on insulin or sulfonylureas), gallbladder problems, kidney issues, serious allergic reactions, and aspiration risk with anesthesia. Two parent-specific ones, stated directly: stop Ozempic 2 months before a planned pregnancy, and breastfeeding isn’t recommended during treatment with the tablets. And tell your provider everything you take, because Wegovy slows stomach emptying, which affects how other medicines move through you.

The everyday part, said honestly

The common side effects are real and some of them are rough: nausea, diarrhea, vomiting, constipation, stomach pain, headache, tiredness, dizziness, bloating, heartburn, hair loss, and low blood sugar in type 2 diabetes. Your stomach will have opinions, at least at first. I’m not going to pretend that part is pleasant, and I’m not going to dramatize it either.

One rule people genuinely don’t know: never share a Wegovy FlexTouch or Ozempic pen, even with a changed needle. Serious infections can pass between people, family members included. Say it kindly, but say it. And since Wegovy is prescription-only, any offer that skips the prescription step isn’t the real medication pathway, the Prescribing Information and Medication Guide exist if you want the full detail before your appointment.

The fine print that changes what you pay: these programs can be modified or canceled by Novo Nordisk at any time, eligibility and restrictions apply to every pathway, prices and coverage can change, and everything here is US-patient pricing. A side effect that forces you to stop ends the spend, but a wasted month is real money. Negative side effects can be reported to FDA MedWatch at www.fda.gov/medwatch or 1-800-FDA-1088. Wegovy is prescription-only, and the full Prescribing Information and Medication Guide exist if you want the complete detail before your appointment.

The answer to what these injections cost is a fork, not a number. Twenty-five dollars a month if you’re commercially insured with the copay card. Fifty dollars a month on the Medicare Bridge, through December 31, 2027. One hundred forty-nine to three hundred ninety-nine dollars a month self-pay through NovoCare depending on dose, with promo rates expiring on specific dates. Or $900 to $1,300-plus at list. Which branch you land on depends on your diagnosis code, your plan type, and how many of the steps above you actually run.

Verify before you commit. The coverage lookup tool, the NovoCare line, and the pharmacist question each take minutes, and they routinely move the number by hundreds of dollars. Budget the standard rate, date every promotional figure, and re-verify at renewal. If you’re weighing what happens down the road, our piece on what happens when you stop weight loss injections covers the part most articles skip, and what is the best injection for weight loss at home walks through the at-home options side by side.

Frequently Asked Questions